Navigation Links
Somnetics' Pioneering CPAP Device Receives the 2012 North American Frost & Sullivan Award for Product Differentiation Excellence
Date:7/18/2012

MOUNTAIN VIEW, Calif., July 18, 2012 /PRNewswire/ -- Based on its recent analysis of the sleep disordered breathing therapeutics market, Frost & Sullivan recognizes Somnetics International, Inc.® with the 2012 North American Frost & Sullivan Award for Product Differentiation Excellence. Somnetics received this award for developing Transcend®, currently the world's smallest, lightest and most portable continuous positive airway pressure (CPAP) system.

Click here for the full multimedia experience of this release ­- http://bit.ly/MldsEg

Increasing awareness about sleep disorders and their economic impact is fueling innovation toward new levels of diagnosis, treatment and management of sleep disordered breathing to enable better long-term clinical outcomes and improving quality of life for patients. Patients also want products that are smarter, smaller, lighter, and provide greater flexibility.

"Somnetics' Transcend represents the culmination of technologic innovation and cutting-edge knowledge within the sleep science community, offering a sustainable option for current and future CPAP users," said Frost & Sullivan Research Industry Analyst Gary Burk. "Small enough to fit into the palm of the hand, it is ideal for travel (FAA approved) as well as permanent night use at home."

Besides size and weight, Transcend's additional differentiator is its patented humidification system. Most conventional humidifiers are an annoyance and require distilled water, constant cleaning and continued maintenance. Transcend's heat moisture exchange (HME) insert is an option that can be integrated into the device, eliminating the need for water-filled humidifiers. The HME is compact, disposable and captures warm moisture from the patient's exhaled breathe and gives it back to the patient as they breathe, providing a comfortable night's sleep.

The Transcend CPAP device also comes with multiple options for true flexibility and individuality. Humidification options include a proprietary HME-compatible mask and nine-inch or six-foot air delivery hose to provide broad flexibility for use. Another option enables the patient to wear the Transcend CPAP for ultimate freedom of movement. Transcend also runs on battery power, offering two long-life battery options for overnight or multiple night use. The integrated battery charger can be used at home or in most vehicles.    

An additional value-add for Transcend users is that the device comes standard with a proprietary interface adaptor that allows the patient to use any CPAP mask on the market while providing true system customization.

"Somnetics' vision to revolutionize and lead the sleep therapy industry by putting the patient first evolved out of acute awareness of unmet sleep market needs as well as an in-depth working knowledge of patients' needs," observed Burk. "Through a truly innovative technology, solid clinical evidence, and a focus on the patient, the company seeks to deliver patient-preferred sleep solutions that will provide sustainable momentum for consumers, patients, investors and the sleep community."

In recognition of these efforts, Frost & Sullivan is proud to present Somnetics International, Inc. with the 2012 North American Frost & Sullivan Award for Product Differentiation Excellence. Each year, Frost & Sullivan presents this award to the company that has developed a product with unique features/functionality as well as high quality for customers with complex needs. The award lauds the degree of the product's customization and the fit for evolving market trends, which ultimately results in a strong brand perception of the product as being unique.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Somnetics International, Inc.

Somnetics International, Inc. is a privately-held medical device company based in Minneapolis, Minn.  It is an emerging leader in customer-driven design, development and production of respiratory medical devices to treat sleep apnea and related issues. Somnetics' mission is focused on integrating technology, customer input and employee creativity to provide innovative, high quality products that improve quality of life for people with respiratory disorders. Transcend received the Innovation Award at Medtrade in October 2011 and the 2012 Best Practices Award for Product Differentiation in the Sleep Disordered Breathing market from Frost & Sullivan.  Somnetics received FDA market clearance for the Transcend CPAP machine in July 2010 and CE Mark in February 2012. Transcend and associated technology is protected by several issued and pending US and foreign patents.  For information about Transcend visit www.mytranscend.com or call 877-621-9626.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation, including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Register:  Gain access to visionary innovation

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
4. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
5. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
6. Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
7. Middle East and Africa Endoscopy Devices Market Outlook to 2017 - Flexible Endoscopes, Rigid Endoscopes, Endoscopy Visualization Systems, Capsule Endoscope Systems and Others
8. Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study
9. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
10. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
11. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage ... gene-based immunotherapeutics and vaccines for the treatment of cancer & ... 3rd Annual Growth Capital Expo to be held ... Caesars Palace in Las Vegas, Nevada.  The Company presentation ... th by Dr. John N. Bonfiglio a ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
(Date:4/27/2016)...   Zillion Group today announced the ... which specializes in live video consultation. Turning content, ... Zillion enables companies to realize the true potential ... control of their health. Zillion,s ... one-to-one, group and webcast scheduled or on-demand – ...
Breaking Medicine Technology:
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... surgeon reveals that infants born with severe congenital diaphragmatic hernia have better survival ... born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, ... ... integrated manufacturer and engineer of patented products, announces the Gyrociser, an exercise invention ... industry is worth $2 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
Breaking Medicine News(10 mins):